ATC Group: L01FF13 Toripalimab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FF13 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
5 L01FF13

Active ingredients in L01FF13

Active Ingredient Description
Toripalimab

Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor. Toripalimab is used for the treatment of melanoma and nasopharyngeal carcinoma.

Related product monographs

Title Information Source Document Type  
LOQTORZI Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.